Evidence map›Paper›PMID 35064687›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2022

Glucocerebrosidase Activity Is Not Associated with Parkinson's Disease Risk or Severity.

Nurit Omer, Nir Giladi, Tanya Gurevich, Anat Bar-Shira, Mali Gana-Weisz, Tal Glinka, Orly Goldstein, Meir Kestenbaum, Jesse M Cedarbaum, Omar S Mabrouk and 5 more

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Glycosphingolipid Changes in Plasma in Parkinson's Disease Independent of Glucosylceramide Levels.Movement disorders : official journal of the Movement Disorder Society · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Nurit OmerMovement Disorders Unit, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.
Nir GiladiMovement Disorders Unit, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.
Tanya GurevichMovement Disorders Unit, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.
Anat Bar-ShiraGenetic Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.
Mali Gana-WeiszGenomic Research Laboratory for Neurodegeneration, Tel-Aviv Medical Center, Tel-Aviv, Israel.
Tal GlinkaGenomic Research Laboratory for Neurodegeneration, Tel-Aviv Medical Center, Tel-Aviv, Israel.
Orly GoldsteinGenomic Research Laboratory for Neurodegeneration, Tel-Aviv Medical Center, Tel-Aviv, Israel.
Meir KestenbaumNeurology Department, Meir Medical Center, Kfar-Saba, Israel.
Jesse M CedarbaumBiogen Inc, Cambridge, Massachusetts, USA.
Omar S MabroukBiogen Inc, Cambridge, Massachusetts, USA.
Kyle B FraserBiogen Inc, Cambridge, Massachusetts, USA.
Julia C ShirvanBiogen Inc, Cambridge, Massachusetts, USA.
Avi Orr-UrtregerSackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Anat MirelmanSackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Avner ThalerMovement Disorders Unit, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.ORCID 0000-0001-7629-8120

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

GlucosylceramidaseParkinson DiseaseDisease SusceptibilityHumansMutationGlucosylceramidase

Identifiers

PMID35064687

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.